Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy

Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy

Saved in:

Bibliographic Details
Main Authors:	Jesse Haramati, Fabiola Solorzano-Ibarra, Dallas B. Flies
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Immunology
Subjects:	ICI Immunotherapy cancer tumor personalized & precision medicine checkpoint blockade (ICB) therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563383/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mitochondria-targeted photothermal-chemodynamic therapy enhances checkpoint blockade immunotherapy on colon cancer
by: Benchao Zheng, et al.
Published: (2025-04-01)

Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade
by: Zhiyang Huang, et al.
Published: (2025-02-01)

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01)

Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
by: Xiuyue Man, et al.
Published: (2025-02-01)

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Yunxiang Hu, et al.
Published: (2025-02-01)

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
by: Toshiaki Tsurui, et al.
Published: (2025-02-01)

Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells
by: Dana Emerson, et al.
Published: (2025-02-01)

Characterization of G2/M checkpoint classifier for personalized treatment in uterine corpus endometrial carcinoma
by: Yiming Liu, et al.
Published: (2025-02-01)

Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages
by: Yuan Li, et al.
Published: (2024-12-01)

Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer
by: Lulu Zhang, et al.
Published: (2025-02-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1
by: Zongfu Pan, et al.
Published: (2025-02-01)

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells
by: Guochen Li, et al.
Published: (2025-02-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Nomograms based on ratio indexes to predict severity and prognosis in immune checkpoint inhibitors-related myocarditis: a retrospective analysis
by: Zhenli Li, et al.
Published: (2024-05-01)

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
by: Keiichiro Suminaga, et al.
Published: (2025-02-01)

Ginseng polysaccharides circumvent acquired resistance to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
by: Jumin Huang, et al.
Published: (2025-02-01)

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial
by: Junya Furukawa, et al.
Published: (2025-02-01)

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
by: Meifeng Luo, et al.
Published: (2025-02-01)

Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma
by: JinSong Li, et al.
Published: (2025-02-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy
by: Weijian Zhu, et al.
Published: (2025-02-01)

Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention
by: Wenhui Hu, et al.
Published: (2025-12-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Vaccine adjuvants for immunotherapy: type, mechanisms and clinical applications
by: Nimeet Desai, et al.
Published: (2025-02-01)

Heterogeneity in polyamine metabolism dictates prognosis and immune checkpoint blockade response in hepatocellular carcinoma
by: Jianyan Pan, et al.
Published: (2025-02-01)

The interplay between persistent pathogen infections with tumor microenvironment and immunotherapy in cancer
by: Si Chen, et al.
Published: (2024-09-01)

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives
by: Dong Luo, et al.
Published: (2025-02-01)

MECHANISMS AND CLINICAL PERSPECTIVES OF ALLERGEN-SPECIFIC IMMUNOTHERAPY
by: Leila Akhvlediani, et al.
Published: (2024-12-01)

Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
by: Yo-Ting Tsai, et al.
Published: (2024-03-01)

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations
by: Sophia Kreft, et al.
Published: (2025-01-01)

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
by: Linghua Wang, et al.
Published: (2023-08-01)

Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer
by: Yuanyuan Wang, et al.
Published: (2025-02-01)

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops
by: Ayaka Kawaguchi, et al.
Published: (2025-03-01)

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors
by: Philippe Rochigneux, et al.
Published: (2025-02-01)

Cyclooxygenase-2/prostaglandin E2 inhibition remodulated photodynamic therapy-associated immunosuppression for enhanced cancer immunotherapy
by: Tao Xu, et al.
Published: (2025-04-01)

Prognostic value of body adipose tissue parameters in cancer patients treated with immune checkpoint inhibitors
by: Yan Li, et al.
Published: (2025-02-01)

Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade
by: Xiaolin Liu, et al.
Published: (2025-02-01)